The clinical performance is complex and often involves multiple systems. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
A comprehensive assessment platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment plans. Treatment and management of HLEBV-related therapies must be individualised, typically including drug therapy, rehabilitation interventions, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adaptation to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL associated with EBV. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.